
|Articles|May 1, 2004
Medicare to cover PDT for select AMD patients
Washington, DC-The Centers for Medicare and Medicaid Services has begun to cover ocular photodynamic therapy (PDT) with verteporfin to treat select patients with subfoveal occult, but no classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and subfoveal minimally classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
PainReform launches development plan for OcuRing-K, readies phase 2 trial
4
Phase 1 trial findings confirm safety and tolerability of Huons’ dry eye therapy
5















































.png)


